Improving Metabolic Monitoring of Atypical Antipsychotics in a Developmental and Behavioral Pediatrics Ambulatory Clinic.

Researchers improved how well doctors monitor children with autism who take certain psychiatric medications. These medications can cause serious health problems like weight gain and diabetes. Before the study, only 31% of children got the required blood tests. After doctors, pharmacists, and nurses worked together to remind families and make testing easier, 64% of children got their tests. Almost half of the children who got tested had concerning results that needed medical attention.

This quality improvement study examined a multidisciplinary intervention to increase metabolic monitoring rates for children with autism spectrum disorder and other neurodevelopmental disorders taking atypical antipsychotic medications. The intervention included pharmacist education, patient identification, nursing phone calls, and child life support services. Baseline monitoring rates were only 31% for required yearly parameters. Following implementation of the multidisciplinary approach, monitoring rates increased to 64% after one year.

Of 141 patients identified as needing monitoring, 51% obtained required tests within 3 months. Notably, 43% of tested patients had abnormal results requiring clinical action, highlighting the importance of systematic monitoring protocols.

Systematic multidisciplinary approaches can significantly improve metabolic monitoring compliance in children with neurodevelopmental disorders taking atypical antipsychotics. The high rate of abnormal findings emphasizes the clinical necessity of consistent monitoring protocols to prevent serious metabolic complications in this vulnerable population.

Single-center quality improvement study limits generalizability. No control group for comparison. Sample size not specified. Study design prevents determination of causality between intervention components and outcomes. Long-term sustainability of improvements not assessed.

Atypical antipsychotics are high-risk medications with serious side effects including weight gain, hyperlipidemia, and insulin resistance. Safe use in youth with autism spectrum disorder and other neurodevelopmental disorders is especially important due to inherent risks of high obesity rates and barriers to a healthy lifestyle. Metabolic monitoring rates are low in this population in part due to difficulties with obtaining labs and other vitals. In our Developmental and Behavioral Pediatrics clinic, 31% of patients had once-yearly metabolic monitoring parameters completed.

We aimed to increase metabolic monitoring rates through multi-disciplinary interventions. A pharmacist provided educational presentations to staff, the pharmacist identified patients needing monitoring and provided recommendations to the medical provider, nursing staff notified families by phone if labs were needed, and child life support services were offered. Average once-yearly metabolic monitoring rates increased from 31% to 64% 1 year after beginning interventions. Three educational presentations were provided, 183 recommendations for monitoring were made on 141 patients, and nursing made 38 phone calls to families.

Of the 141 patients identified as needing monitoring at the time of clinic visit, 72 (51%) obtained the monitoring parameters within 3 months. Abnormal metabolic labs requiring additional action were found in 31/72 (43%) patients. Patients with in-person visits were more likely to obtain labs overall and on the day of clinic visit than those with telehealth appointments. Using a multidisciplinary approach within a Developmental and Behavioral Pediatrics clinic, metabolic monitoring rates in patients taking atypical antipsychotics greatly improved.